Increasing Hepatitis C treatment uptake among HIV-infected patients using an HIV primary care model

AIDS Research and Therapy

William C Mathews³  David Wyles²  Francesca Torriani²  Bradford Colwell¹  Craig Ballard¹  Lucas Hill¹  Edward R Cachay² 

[1]Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California at San Diego, San Diego, CA, USA

[2]Department of Medicine, Division of Infectious Diseases, University of California at San Diego, San Diego, CA, USA

[3]Department of Medicine, Owen Clinic, University of California at San Diego, 200 W. Arbor Drive, San Diego, CA, 92103-8681, USA

关键词: Hepatology;    Primary care;    HCV treatment;    HIV;   

Others  :  789602
DOI  :  10.1186/1742-6405-10-9

 received in 2013-02-04, accepted in 2013-03-21,  发布年份 2013

【 摘 要 】

Background

Access to Hepatitis C (HCV) care is low among HIV-infected individuals, highlighting the need for new models to deliver care for this population.

Methods

Retrospective cohort analysis that compared the number of HIV patients who initiated HCV therapy: hepatology (2005–2008) vs. HIV primary care model (2008–2011). Logistic-regression modeling was used to ascertain factors associated with HCV therapy initiation and achievement of sustained viral response (SVR).

Results

Of 196 and 163 patients that were enrolled in the HIV primary care and hepatology models, 48 and 26 were treated for HCV, respectively (p = 0.043). The HIV/HCV-patient referral rate did not differ during the two study periods (0.10 vs. 0.12/patient-yr, p = 0.18). In unadjusted analysis, predictors (p < 0.05) of HCV treatment initiation included referral to the HIV primary care model (OR: 1.7), a CD4+ count ≥400/mm3 (OR: 1.8) and alanine aminotranferase level ≥63U/L (OR: 1.9). Prior psychiatric medication use correlated negatively with HCV treatment initiation (OR: 0.6, p = 0.045). In adjusted analysis the strongest predictor of HCV treatment initiation was CD4+ count (≥400/mm3, OR: 2.1, p = 0.01). There was no significant difference in either clinic model (primary care vs. hepatology) in the rates of treatment discontinuation due to adverse events (29% vs. 16%), loss to follow-up (8 vs. 8%), or HCV SVR (44 vs. 35%).

Conclusions

Using a HIV primary care model increased the number of HIV patients who initiate HCV therapy with comparable outcomes to a hepatology model.

【 授权许可】

   
2013 Cachay et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Scott JD, Wald A, Kitahata M: Hepatitis C virus is infrequently evaluated and treated in an urban HIV clinic population. AIDS Patient Care STDS 2009, 23:925-929.
• [2]Vellozzi C, Buchacz K, Baker R: Treatment of hepatitis C virus (HCV) infection in patients coinfected with HIV in the HIV Outpatient Study (HOPS), 1999–2007. J Viral Hepat 2011, 18:316-324.
• [3]Reiberger T, Obermeier M, Payer BA: Considerable under-treatment of chronic HCV infection in HIV patients despite acceptable sustained virological response rates in a real-life setting. Antivir Ther 2011, 16:815-824.
• [4]Gordon S, Pockros P, Terrault N: Impact of disease severity on health care costs in patients with chronic hepatitis C (CHC) virus infection. Hepatology 2012, 56:1651-1660.
• [5]Norton BL, Park L, McGrath LJ, Proeschold Bell RJ, Muir AJ, Naggie S: Health care utilization in HIV-infected patients: assessing the burden of hepatitis C virus coinfection. AIDS Patient Care STDS 2012, 26:541-545.
• [6]Goulet JL, Fultz SL, McGinnis KA, Justice AC: Relative prevalence of comorbidities and treatment contraindications in HIV-mono-infected and HIV/HCV-co-infected veterans. AIDS 2005, 19(Suppl 3):S99-S105.
• [7]Golden J, O'Dwyer AM, Conroy RM: Depression and anxiety in patients with hepatitis C: prevalence, detection rates and risk factors. Gen Hosp Psychiatry 2005, 27:431-438.
• [8]Fleming CA, Tumilty S, Murray JE, Nunes D: Challenges in the treatment of patients coinfected with HIV and hepatitis C virus: need for team care. Clin Infect Dis 2005, 40(Suppl 5):S349-S354.
• [9]Lekas HM, Siegel K, Leider J: Challenges facing providers caring for HIV/HCV-coinfected patients. Qual Health Res 2012, 22:54-66.
• [10]Astell-Burt T, Flowerdew R, Boyle P, Dillon J: Is travel-time to a specialist centre a risk factor for non-referral, non-attendance and loss to follow-up among patients with hepatitis C (HCV) infection? Soc Sci Med 2012, 75:240-247.
• [11]Preau M, Protopopescu C, Raffi F: Satisfaction with care in HIV-infected patients treated with long-term follow-up antiretroviral therapy: the role of social vulnerability. AIDS Care 2012, 24:434-443.
• [12]Ghany MG, Strader DB, Thomas DL, Seff LB: Diagnosis, management and treatment of hepatitis C: un update. Hepatology 2009, 49:1335-1374.
• [13]WHO ASSIST Working Group: The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): development, reliability and feasibility. Addiction 2002, 97:1183-1194.
• [14]Curcio F, Di Martino F, Capraro C: Together … to take care: multidisciplinary management of hepatitis C virus treatment in randomly selected drug users with chronic hepatitis. J Addict Med 2010, 4:223-232.
• [15]Ford N, Singh K, Cooke GS: Expanding access to treatment for hepatitis C in resource-limited settings: lessons from HIV/AIDS. Clin Infect Dis 2012, 54:1465-1472.
• [16]Kieran J, Dillon A, Farrell G: High uptake of hepatitis C virus treatment in HIV/hepatitis C virus co-infected patients attending an integrated HIV/hepatitis C virus clinic. Int J STD AIDS 2011, 22:571-576.
• [17]Parry J: HIV groups have much to teach hepatitis doctors about better diagnosis and treatment. BMJ 2012, 344:e1266.
• [18]Ingiliz P, Rockstroh JK: HIV-HCV co-infection facing HCV protease inhibitor licensing: implications for clinicians. Liver Int 2012, 32:1194-1199.
• [19]Cachay ER, Wyles DL, Goicoechea M: Reliability and predictive validity of a hepatitis-related symptom inventory in HIV-infected individuals referred for hepatitis C treatment. AIDS Res Ther 2011, 8:e29. BioMed Central Full Text
• [20]Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB: Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
• [21]Morse DS, Schiff M, Levit S, Cohen-Moreno R, Williams GC, Neumark Y: A pilot training program for a motivational enhancement approach to hepatitis C virus treatment among individuals in Israeli methadone treatment centers. Subst Use Misuse 2012, 47:56-66.
• [22]Joshi D, O'Grady J, Dieterich D, Gazzard B, Agarwal K: Increasing burden of liver disease in patients with HIV infection. Lancet 2011, 377:1198-1209.
• [23]Moak ZSD, Osinusi A, Silk R, Kotb C: Community engagement in a unique federal-local partnership: A model for hepatitits care and research [Abstract WEPE051]. Program and abstracts of the19th International AIDS Conference July 22–27. Washington DC, USA 2012.
• [24]Grint D, Peters L, Vogel M, Beniowski M, Pradier C, Battegay M, Jevtovic D, Soriano V, Lundgren J, Rockstroh J, Kirk O, Mocroft A: Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA [Abstract 0243]. Posters and abstracts of the Eleventh International Congress on Drug Therapy in HIV Infection, Glasgow 2012.
• [25]Rourke SB, Sobota M, Tucker R: Social determinants of health associated with hepatitis C co-infection among people living with HIV: results from the Positive Spaces, Healthy Places study. Open Med 2011, 5:e120-e131.
• [26]McHutchison JG, Everson GT, Gordon SC: Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009, 360:1827-1838.
• [27]Poordad F, McCone J Jr, Bacon BR: Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011, 364:1195-1206.
• [28]Lambert SM, Page AN, Wittmann J: General practitioner attitudes to prescribing hepatitis C antiviral therapy in a community setting. Aust J Prim Health 2011, 17:282-287.
• [29]Hall CS, Charlebois ED, Hahn JA, Moss AR, Bangsberg DR: Hepatitis C virus infection in San Francisco's HIV-infected urban poor. J Gen Intern Med 2004, 19:357-365.
• [30]Poveda E, Vispo E, Barreiro P, de Mendoza C, Labarga P, Fernández-Montero JV, Martin-Carbonero L, Soriano V: Predicted effect of direct acting antivirals in the current HIV-HCV-coinfected population in Spain. Antivir Ther 2012, 17:571-575.